mTOR inhibitors are part of ongoing trials regarding hormone receptor-positive treatment resistant tumours, although the apparent involvement of PI3K/mTOR in bone makes it of interest for bone metastasis (Royce & Osman 2015, Zhang et al. 2016). Here, NR4A1 is linked to neoplasm.